Looking at ADCs, PI3K Inhibitors, and Oral SERDs That Drive Practice-Changing Breast Cancer Readouts at ASCO 2026

From the final overall survival verdict on a landmark immunotherapy trial to a dual-targeting antibody challenging a decade-old HER2 standard, breast cancer arrives at ASCO 2026 with a slate spanning every major subtype and some of the field’s most consequential unanswered questions.

Breast cancer is the world’s most commonly diagnosed cancer, but it is not one disease. Hormone receptor-positive, HER2-positive, and triple-negative breast cancers each carry distinct biology, treatment paradigms, and mechanisms of resistance. At ASCO 2026, major presentations across all three subtypes are poised to influence frontline care, treatment sequencing, and future drug development strategies.

KEYNOTE-522 Delivers the Survival Verdict on Immunotherapy in Early TNBC

Abstract LBA500 | Trial: NCT03036488

Triple-negative breast cancer (TNBC) is defined by what it lacks: estrogen receptors, progesterone receptors, and HER2 expression — the three targets most breast cancer therapies exploit. Without those targets, chemotherapy historically remained the primary systemic treatment, and outcomes were generally poorer than in other breast cancer subtypes, particularly for patients with residual disease after surgery.

Pembrolizumab changed that landscape through the phase 3 KEYNOTE-522 study. The trial evaluated pembrolizumab added to standard neoadjuvant chemotherapy before surgery, followed by adjuvant pembrolizumab afterward. Earlier analyses demonstrated significant improvements in pathologic complete response and event-free survival, supporting FDA approval in 2021. ASCO 2026 now delivers the mature overall survival analysis — the endpoint that ultimately determines whether patients live longer with the regimen.

Why it matters: Final overall survival confirmation establishes the definitive benchmark for early-stage TNBC immunotherapy and will influence future trial design, reimbursement decisions, and global treatment standards.

VIKTORIA-1 Tests Whether Broader PI3K Blockade Can Reshape Post-CDK4/6 Breast Cancer Care

Late-Breaking Abstract LBA1008 | Trial: NCT05501886

Approximately 40% of hormone receptor-positive, HER2-negative metastatic breast cancers harbor mutations in PIK3CA, a key driver of the PI3K/AKT/mTOR signaling pathway. Existing PI3K inhibitors have validated the pathway as therapeutically relevant, but toxicity — particularly hyperglycemia and rash — has limited broader adoption.

Gedatolisib takes a broader pathway approach through simultaneous pan-PI3K and mTOR inhibition. VIKTORIA-1 enrolls patients whose disease progressed following CDK4/6 inhibitor therapy combined with endocrine treatment. A May 2026 company release confirmed the PIK3CA-mutant cohort met its primary endpoint, demonstrating progression-free survival improvement with gedatolisib plus fulvestrant versus standard therapy. ASCO 2026 is expected to provide the first detailed presentation of efficacy magnitude, durability, and safety.

Why it matters: The post-CDK4/6 setting remains one of the most strategically important areas in metastatic breast cancer. A broader and potentially more tolerable PI3K/mTOR inhibitor could substantially alter endocrine treatment sequencing.

ASCENT-04 Pushes ADC-Immunotherapy Combinations Into Frontline Metastatic TNBC

Abstract LBA1000 | Trial: NCT05382286

Metastatic TNBC continues to carry poor long-term outcomes despite recent therapeutic advances. Two of the most promising developments in recent years have been immune checkpoint inhibition and antibody-drug conjugates (ADCs). ADCs combine targeted antibodies with highly potent cytotoxic payloads, delivering chemotherapy more selectively to cancer cells.

Sacituzumab Govitecan targets TROP-2, a protein highly expressed in TNBC. ASCENT-04 evaluates sacituzumab govitecan combined with pembrolizumab against pembrolizumab plus chemotherapy in previously untreated PD-L1-positive metastatic TNBC. ASCO selected the study for its official press program, underscoring its potential clinical significance.

Why it matters: If the ADC-immunotherapy strategy outperforms pembrolizumab plus chemotherapy, it could redefine frontline metastatic TNBC treatment while reinforcing a broader oncology trend toward combining ADCs with checkpoint inhibitors across tumor types.

A Next-Generation HER2 Antibody Challenges a Two-Decade Standard in Early Breast Cancer

Abstract LBA660 | Trial: NCT06747338

HER2-positive breast cancer has been transformed by HER2-directed therapies over the past two decades. The current neoadjuvant standard for high-risk disease combines trastuzumab and pertuzumab with chemotherapy — the THP regimen established through pivotal HER2 trials.

Anbenitamab introduces a different HER2-targeting strategy. Rather than combining two antibodies, anbenitamab is a biparatopic antibody engineered to bind two separate HER2 regions simultaneously, promoting receptor internalization and degradation. KN026-004 compares anbenitamab plus nab-docetaxel against standard THP-based therapy in HER2-positive early or locally advanced breast cancer. Pre-meeting disclosures reported significantly improved total pathologic complete response rates.

Why it matters: Novel HER2-targeting architectures could expand options beyond current antibody and ADC approaches, particularly in earlier-stage disease where maximizing pathological complete response remains central to long-term outcomes.

persevERA Defines the Limits — and Potential — of Oral SERDs in Frontline Breast Cancer

Late-Breaking Abstract LBA1006 | Trial: NCT04546009

Hormone receptor-positive, HER2-negative metastatic breast cancer represents the majority of metastatic breast cancer cases. Standard frontline therapy pairs endocrine treatment with CDK4/6 inhibition, but resistance eventually develops in nearly all patients.

Giredestrant belongs to the emerging oral SERD class, which not only blocks estrogen signaling but actively degrades the estrogen receptor itself. The phase 3 persevERA trial compared giredestrant plus palbociclib against letrozole plus palbociclib in previously untreated HR+/HER2-negative advanced breast cancer. A March 2026 company release confirmed the trial did not meet its primary endpoint in the overall study population. However, ASCO 2026 data are expected to clarify whether specific subgroups — particularly patients with ESR1 mutations — may still derive benefit.

Why it matters: Even negative frontline endocrine trials meaningfully shape the field. The persevERA results may help define where oral SERDs add value, how ESR1 mutations should guide treatment decisions, and how future endocrine sequencing strategies evolve.

The Bigger Picture in Breast Cancer at ASCO 2026

Several themes connect this year’s breast cancer presentations. ADCs continue moving earlier in treatment, with ASCENT-04 testing whether sacituzumab govitecan belongs in frontline metastatic TNBC. Novel therapeutic architectures — including biparatopic HER2 targeting and multi-pathway PI3K/mTOR inhibition — are testing whether more sophisticated molecular strategies can outperform established standards. Mature survival data from KEYNOTE-522 continue defining immunotherapy’s role in early TNBC, while negative studies such as persevERA remain equally important in clarifying the boundaries of benefit for emerging endocrine drug classes.

Author

Bernice Lottering